Phase I study of S 78454 in combination with radiotherapy in patients with solid tumour Not provided at time of registration and not expected to be available in the future

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Phase I study of S 78454 given with a fixed dose infusion of pegylated liposomal doxorubicin in the treatment of primary epithelial ovarian, fallopian tube or primary peritoneal carcinoma Not provided at time of registration and not expected to be available in the future

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Phase I study of S 78454 in the treatment of patients with acute myeloid leukemia, acute lymphoblastic leukemia or myelodysplastic syndrome Not provided at time of registration and not expected to be available in the future

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors Phase 1b: Primary Objective: - To determine the recommended Phase 2 dose (RP2D) of ibrutinib in combination with everolimus in RCC, paclitaxel in urothelial carcinoma, docetaxel in gastric adenocarc...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Estudio de fase III, aleatorizado, multicéntrico y abierto, del inhibidor de la tirosina-cinasa de Bruton (BTK) ibrutinib frente a ofatumumab en pacientes con leucemia linfocítica crónica/linfoma linfocítico pequeño recidivante o resistente a tratamiento. A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton?s Tyrosine Kinase (BTK) Inhibitor Ibrutinib versus Ofatumumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Evaluar la eficacia de ibrutinib en comparación con ofatumumab basándose en la opinion del comité revisor independiente (CRI) en pacientes con LLC/LLP recidivante o resistente a tratamiento Evaluar...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A study to evaluate use of PCI-32765 (Ibrutinib) in Patients with Leukemia The primary objective of this study is to evaluate the efficacy of PCI-32765 in terms of ORR according to an Independent Review Committee (IRC) per International Workshop on Chronic Lymphocytic Leukem...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Phase I/II dose-escalation study of S 78454 in Lymphoma Phase I part: - To assess the MTDs and the dose-limiting toxicities (DLTs) for each dosing schedule tested. - To determine the optimal dosing schedule and its associated recommended Phase II dose. ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Clinical Study of Rituximab with Ibrutinib Compared to Rituxumab Alone, and Subsequently of Ibrutinib Alone Compared to Placebo in Treatment Naïve Subjects with Follicular Lymphoma Un estudio clinico de rituximab con ibrutinib comparado con rituximab sólo, y posteriormente de ibrutinib sólo comparado con placebo en sujetos sin tratamiento previo con linfoma folicular Analysis Study 1 To evaluate whether the addition of ibrutinib to rituximab will result in prolongation of progression-free survival (PFS) when compared with rituximab alone in treatment naïve subject...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Safety and Efficacy of ibrutinib in combination with lenalidomide and rituximab in patients with previously treated Diffuse Large B-Cell Lymphoma Primary Objective: • To evaluate the efficacy of ibrutinib in combination with lenalidomide and rituximab by assessing the overall response rate (ORR) in subjects with relapsed or refractory non-GC...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Phase I study of S 78454 with tamoxifen 20 mg in patients with breast cancer Not provided at time of registration and not expected to be available in the future

• Pays Aucun
• Organes Aucun
• Spécialités Aucune